ASXQuarterly Activities Report and Appendix 4C
other announcement
NYR
Pharmaceuticals, Biotechnology & Life Sciences
Nyrada
- Short interest
- 0.01%
- +0.01 pp 30d
- as of 19 Oct 2026
- Reported shorts
- 27.9K
- Shares on issue
- 258.682M
Nyrada (NYR) News
Latest articles and price-sensitive announcements with AI sentiment classification.
PROTECT-MI Phase IIa Clinical Trial Update No 3
other announcement
Nyrada Receives Positive FDA Feedback
other announcement
Securities Purchase Plan Offer Booklet
other announcement
2026 AGM Letter to Shareholders, Notice of Meeting & Proxy
other announcement
Nyrada US Patent for Xolatryp Granted
other announcement
Application for quotation of securities - NYR
other announcement
Proposed issue of securities - NYR
other announcement
Proposed issue of securities - NYR
other announcement
Proposed issue of securities - NYR
other announcement
Proposed issue of securities - NYR
other announcement
Cap Raise Deck-Building the Future of TRPC-based Therapies
other announcement
Nyrada Successfully Raises AU$12.0 Million Via Placement
capital_raise announcement
Investor Presentation- Evans&Partners Small Cap Healthcare
other announcement
Xolatryp Demonstrates Cardioprotection in Preclinical Study
other announcement
Google NewsBeyond the Daily Move: What Investors Are Watching at Nyrada (ASX:NYR)? - Kalkine
Beyond the Daily Move: What Investors Are Watching at Nyrada (ASX:NYR)? Kalkine
Nyrada (ASX:NYR) Shares Rise Over 7%: What Put the Biotechnology Stock in Focus? - Kalkine
Nyrada (ASX:NYR) Shares Rise Over 7%: What Put the Biotechnology Stock in Focus? Kalkine
Several Insiders Invested In Nyrada Flagging Positive News - simplywall.st
Several Insiders Invested In Nyrada Flagging Positive News simplywall.st
Nyrada Inc (ASX:NYR) Surges 38.55% as Healthcare Stock Extends One-Year Gain - Kalkine
Nyrada Inc (ASX:NYR) Surges 38.55% as Healthcare Stock Extends One-Year Gain Kalkine
Change of Director's Interest Notice - JB
director_dealing announcement
Nyrada Successfully Completes Cardioprotection Pilot Study
other announcement
KalkineNyrada Gains Market Attention Amid Growth Momentum
Highlights Strong innovation focus continues to attract market interest Cash position remains closely watched by investors Revenue expansion reflects business development momentum Nyrada is gaining attention for its expanding business activity, innovation-driven approach, and improving revenue profile, even as investors continue monitoring its cash management strategy and long-term growth direction. Biotechnology and healthcare innovation companies often attract investor interest when b...
Here's Why We're Not Too Worried About Nyrada's (ASX:NYR) Cash Burn Situation - simplywall.st
Here's Why We're Not Too Worried About Nyrada's (ASX:NYR) Cash Burn Situation simplywall.st
Xolatryp Enhances Anthracycline Anti-Tumour Efficacy
other announcement
Nyrada Strengthens Innovation Push With Xolatryp Patent Progress
Highlights Nyrada advances intellectual property footprint in the US Xolatryp development gains momentum in cardiac care research Patent progress strengthens long-term innovation pathway Nyrada’s latest US patent development for Xolatryp highlights growing momentum in advanced cardiac therapy research, strengthening its innovation profile and expanding attention across the biotechnology landscape. Australian biotechnology company Nyrada (ASX:NYR) has reached an important milestone...
Nyrada Receives Notice of Allowance for Xolatryp US Patent
other announcement
First Site Activated in Nyradas PROTECT-MI Phase IIa Trial
other announcement